Ranieri E, Gigante M, Storkus W J, Gesualdo L
Clinical Pathology, Department of Biomedical Sciences, University of Foggia, Italy.
Clin Exp Immunol. 2007 Mar;147(3):395-400. doi: 10.1111/j.1365-2249.2006.03305.x.
Renal cancer is a relatively uncommon solid tumor, accounting for about 3% of all adult malignancies, however this rate incidence is rising. The most common histological renal cell carcinoma (RCC) subtype is clear cell carcinoma that makes up approximately 70-80% of all renal neoplasms and appears to be the only histological subtype that is responsive to immunotherapeutic approaches with any consistency. Therefore, it has been hypothesized that immune-mediated mechanisms play important roles in limiting tumor growth and that dendritic cells (DC), the most potent APC in the body, and T cells are the dominant effector cells that regulate tumor progression in situ. In this context, the development of clinically effective DC-based vaccines is a major focus for active specific immunotherapy in renal cancer. In the current review we have not focused on the results of recently published RCC clinical trials, as several excellent reviews have already performed this function. Instead, we turned our attention to how the perception and practical application of DC-based vaccinations are evolving.
肾癌是一种相对不常见的实体瘤，约占所有成人恶性肿瘤的3%，然而这一发病率正在上升。最常见的组织学类型的肾细胞癌（RCC）亚型是透明细胞癌，约占所有肾肿瘤的70-80%，并且似乎是唯一对免疫治疗方法有任何一致性反应的组织学亚型。因此，有人推测免疫介导机制在限制肿瘤生长中起重要作用，并且树突状细胞（DC），体内最有效的抗原呈递细胞，和T细胞是调节肿瘤原位进展的主要效应细胞。在这种背景下，开发基于DC的临床有效疫苗是肾癌主动特异性免疫治疗的主要重点。在当前的综述中，我们没有关注最近发表的RCC临床试验结果，因为已有几篇优秀的综述履行了这一职能。相反，我们将注意力转向基于DC的疫苗接种的认知和实际应用是如何演变的。
